LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 7,752 Shares

Key Points

• Director Robert Bessler sold a total of 75,000 shares across April 21–24 for about $528,158, and still directly owns 1,305,521 shares valued at roughly $9.14 million.
• LifeStance shares traded at about $7.27 with elevated volume, the board approved a $100 million share buyback (≈3.6% of shares), and analysts hold a consensus of "Moderate Buy" with an average target of $9.83.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 7,752 shares of the firm's stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $7.00, for a total transaction of $54,264.00. Following the sale, the director directly owned 1,305,521 shares of the company's stock, valued at $9,138,647. This trade represents a 0.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Bessler also recently made the following trade(s):

• On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total transaction of $438,136.35.
• On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $35,758.01.

LifeStance Health Group Stock Performance

NASDAQ:LFST traded up $0.22 during trading hours on Monday, reaching $7.27. The company had a trading volume of 3,942,208 shares, compared to its average volume of 2,098,770. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.09. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of 363.68 and a beta of 1.13. The firm's 50 day moving average price is $6.73 and its 200-day moving average price is $6.56.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.The company had revenue of $382.20 million during the quarter, compared to the consensus estimate of $378.51 million. During the same period last year, the firm posted ($0.01) EPS. The company's revenue for the quarter was up 17.4% on a year-over-year basis. On average, analysts forecast that LifeStance Health Group, Inc. will post 0.09 EPS for the current year.

LifeStance Health Group announced that its board has approved a share repurchase program on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to buy up to 3.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds have recently modified their holdings of LFST. Larson Financial Group LLC grew its position in shares of LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock valued at $27,000 after acquiring an additional 3,791 shares during the period. Bayesian Capital Management LP bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at $52,000. Krane Funds Advisors LLC bought a new stake in shares of LifeStance Health Group during the 4th quarter valued at $71,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of LifeStance Health Group during the 3rd quarter valued at $72,000. Finally, Cibc World Markets Corp bought a new stake in shares of LifeStance Health Group during the 4th quarter valued at $77,000. Institutional investors own 85.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings raised shares of LifeStance Health Group from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, February 27th. UBS Group lifted their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Sunday, February 8th. Barclays lifted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a research report on Friday, March 6th. Finally, BTIG Research boosted their price objective on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and an average price target of $9.83.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.